ASSESSMENT OF 4 MONOCLONAL-ANTIBODIES AS SERUM MARKERS IN BREAST-CANCER

被引：27

作者：

ROBERTSON, JFR

PEARSON, D

PRICE, MR

SELBY, C

BADLEY, RA

PEARSON, J

BLAMEY, RW

HOWELL, A

机构：

[1] CITY HOSP NOTTINGHAM,MED PHYS UNIT,NOTTINGHAM NG5 1PD,ENGLAND

[2] UNIV NOTTINGHAM HOSP,COMMUNITY MED UNIT,NOTTINGHAM NG7 2UH,ENGLAND

[3] CANC RES CAMPAIGN,NOTTINGHAM,ENGLAND

[4] UNILEVER RES LABS,SHARNBROOK MK44 1LQ,BEDS,ENGLAND

[5] CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1990年 / 26卷 / 11-12期

关键词：

D O I：

10.1016/0277-5379(90)90268-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Four monoclonal-antibody-defined serum markers (CA15-3, HMFG1, HMFG2 and NCRC-11) were examined in five groups of subjects: controls, benign breast disease and stage I/II, stage III and metastatic breast cancer. None of the markers were significantly elevated in primary breast cancer (i.e. stage I/II or stage III) compared with controls or patients with benign breast disease. These markers therefore have no role in screening or in the diagnosis of primary breast cancer. CA15-3, HMFG2 and NCRC-11 were significantly increased in the patients with metastatic breast cancer (P < 0.001), indicating a potential use in the diagnosis of symptomatic metastases. In patients with metastases, sequential changes in CA15-3 correlated significantly with clinical response to therapy. Thus CA15-3 is a powerful marker of response and in combination with other markers, may provide an objective measurement of response to therapy in patients with advanced breast cancer.

引用

页码：1127 / 1132

页数：6

共 31 条

[1] DIFFERENTIATION ANTIGENS EXPRESSED BY EPITHELIAL-CELLS IN THE LACTATING BREAST ARE ALSO DETECTABLE IN BREAST CANCERS [J].